Dr | Research Officer
Dr Jasmin Straube received her PhD in developing statistical methods and tools for the analysis and integration of ‘omics data from the University of Queensland in 2017.
Following this she joined Prof. Steven Lane’s group at QIMR Berghofer where she investigates how mutations in haematopoietic stem cells lead to the development of myeloid blood cancers and therapy resistance.
She led a study assessing the genetic risk of responding to chemotherapy in acute myeloid leukaemia (AML). This data helps clinicians to decide how to treat AML patients. She also was a lead author on a study that identified AML oncogenes vary in their potential to interact with the immune system, which will inform the implementation of immunotherapies in the clinic.
Her current research focuses on developing sequencing and bioinformatics methods to study how complex genetic heterogeneity in myeloid blood cancer patient haematopoietic stem cells contribute to therapy resistance and disease progression. Additionally, she is working to identify novel strategies that can effectively eliminate myeloid cancer-driving stem cells, ultimately improving patient treatment and outcomes.
Dr Straube’s research focuses on the analysis and integration of next generation sequence data to study myeloid blood cancers, which are aggressive cancers with one of the poorest survival rates in Australia.
She has highly developed bioinformatics expertise and uses it to study mutation-driven epigenetic and transcriptomic changes in haematopoietic stem cells and how this leads to transformation into myeloid blood cancers and treatment resistance.
She has a keen interest to integrate `big` genomic data to identify rational targeted therapies.
Ultimately, she aims to generate data that help to design and implement ‘personalised’ therapies to improve myeloid blood cancer patient outcomes.
Using genomics and clinical data she has identified AML genetic factors with prognostic implications, published in the top-ranking haematology journal and used to develop new genetic risk classifications of AML. This work was highly regarded at the 2018 Research Excellence Awards Metro North – Discovery and Innovation, recognising excellence in research by QLD largest hospital.
STRAUBE* et al. The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. BLOOD 2018 PMID: 32286286
She has investigated informed scheduling of treatment in myeloid cancers and identified mechanisms of treatment response with data used for the FDA filing and subsequent clinical approval of oral azacitidine as maintenance therapy in AML .
Vu, STRAUBE et al. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. NATURE COMMUNICATIONS 2020 PMID: 32286286
We assessed the immunogenic potential of AML oncogenic drivers and generated data that will inform the design and implementation of immunotherapies in AML.
Austin*, STRAUBE* et al. Oncogenic drivers dictate immune control of acute myeloid leukemia NATURE COMMUNICATIONS, 14, 2155 (2023). https://doi.org/10.1038/s41467-023-37592-9